Temporal changes to adult case fatality risk of COVID-19 after vaccination in England between May 2020 and February 2022: a national surveillance study
- 14 December 2023
- journal article
- research article
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 117 (6) , 202-211
Abstract
Objectives: Risk of death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has fallen during the pandemic, largely due to immunity from vaccination. In England, the timing and extent of this reduction varied due to staggered eligibility during the primary vaccination campaign, based on age and clinical risk group. Duration of protection is less well understood. Our objective was to estimate the case fatality risk (CFR) by vaccination status and time since last dose during a period of widespread community testing, to better understand the impact of coronavirus disease 2019 (COVID-19) vaccination and duration of protection. Design: SARS-CoV-2 cases diagnosed between May 2020 and February 2022 were linked to vaccine records from the National Immunisation Management System. CFR was calculated as the proportion of cases that died of COVID-19 per the death certificate, aggregated by week of specimen and stratified by 10-year age band and vaccination status. Setting: England, UK. Participants: A total of 10,616,148 SARS-CoV-2 cases, aged ≥18 years, recorded by England’s laboratory reporting system. Main outcome measures: Case fatality risk of COVID-19, stratified by age band and vaccination status. Results: Overall, a reduction in CFR was observed for all age bands, with a clear temporal link to when the age group became eligible for primary vaccination and then the first booster. CFR increased with age (0.3% 50–59 years; 1.2% 60–69; 4.7% 70–79; 16.3% 80+) and was highest in the unvaccinated – albeit a reduction was observed over time. The highest CFR was seen in the unvaccinated 80+ group prior to vaccination rollout (30.6%). CFR was consistently lowest in vaccinated populations within 6 months of last dose, yet increased after over 6 months elapsed since last dose, across all age bands. Conclusions: COVID-19 CFR reduced after vaccination, with the lowest CFR seen across all age bands when vaccinated up to 6 months prior to specimen date. This provides some evidence for continued booster doses in older age groups.Keywords
This publication has 10 references indexed in Scilit:
- Evaluation of Waning of SARS-CoV-2 Vaccine–Induced ImmunityJAMA Network Open, 2023
- Monitoring the COVID-19 immunisation programme through a national immunisation Management system – England’s experienceInternational Journal of Medical Informatics, 2022
- Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control studyBMJ, 2022
- Variation in reported SARS-CoV-2 cases after testing policy changesThe Lancet Infectious Diseases, 2022
- Lateral flow assays for viruses diagnosis: Up-to-date technology and future prospectsTrAC Trends in Analytical Chemistry, 2022
- COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID StudyThe Lancet Infectious Diseases, 2022
- Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regressionThe Lancet, 2022
- Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in EnglandNature Communications, 2021
- Interpretation of COVID-19 case fatality risk measures in EnglandJournal of Epidemiology and Community Health, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021